Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 2022 Business Objectives—-

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Feb 24, 2022 10:31am

135 Views

Post# 34457882

RE:RE:RE:2022 Business Objectives—-

It seems that this is the case but negotiations are ongoing...Reported Trogarzo sales were negatively impacted in the 4 th quarter by a clawback ,,,,It appears that they had to issue a credit note in the 4 th quarter for sales recorded in the previous quarter due to overcharging over reimbursement in France....Not clear as they were not ready to provide more details

qwerty22 wrote:
fostensavir's agreed price (with the French) is driving down the negotiated price of Trogarzo there???

palinc2000 wrote: I think we are seeing a shift back to commercial operations!
Big disappointment for those looking for overnight riches